The top pain management device companies in 2026 are Medtronic, Abbott and Boston Scientific. iData Research values the U.S. pain management device market at $6.2 billion in 2025, growing at a 3.4% CAGR toward $7.8 billion. These three leaders hold the strongest positions across spinal cord stimulation, deep brain stimulation and radiofrequency ablation.
Find growth niches in minutes, not months.
Explore quick, actionable insights from the select markets.
Table of Contents
➜ Who are the top pain management device companies in 2026?
➜ Why Medtronic leads the pain management device market
➜ What makes Abbott a top pain management device company
➜ Why Boston Scientific ranks among the top pain management companies
➜ How big is the U.S. pain management device market?
➜ Pain management device companies: frequently asked questions
Key Takeaways
Medtronic, Abbott and Boston Scientific are the three leading pain management device companies in the U.S. in 2026, according to iData Research.
Medtronic ranks first, with strong positions in spinal cord stimulation, deep brain stimulation, intrathecal pumps and radiofrequency ablation.
Abbott ranks second, led by its Proclaim and Eterna spinal cord stimulation systems and its radiofrequency ablation portfolio.
Boston Scientific ranks third, built on its Vercise Genus deep brain stimulation system and a full radiofrequency ablation line.
The U.S. pain management device market is worth $6.2 billion in 2025 and is forecast to reach $7.8 billion, a 3.4% CAGR, driven by demand for non-opioid pain relief.
Who are the top pain management device companies in 2026?
The top pain management device companies in 2026 are Medtronic, Abbott and Boston Scientific, in that order.
iData Research values the U.S. pain management device market at $6.2 billion in 2025. Medtronic leads overall, followed by Abbott and then Boston Scientific. All three hold significant share across spinal cord stimulation, deep brain stimulation and radiofrequency ablation.
Below the top three, the market is highly specialized across 13 device segments. In individual categories, other firms lead: NeuroPace in responsive neurostimulation, Stryker in radiofrequency ablation, GE Healthcare in anesthesia point-of-care ultrasound, and Baxter, Becton Dickinson, ICU Medical and B. Braun across the infusion pump categories.
For the full ranking of pain management device companies, iData Research tracks market share across every one of these segments.
Why Medtronic leads the pain management device market
Medtronic is the leading pain management device company in the U.S.
It holds significant share in spinal cord stimulation, deep brain stimulation, intrathecal pumps and radiofrequency ablation, according to iData Research. As the first company to bring a spinal cord stimulation product to market, Medtronic built long-standing relationships with physicians and strong brand recognition.
Its portfolio includes the RESTORE neurostimulator line and Activa deep brain stimulation systems. The report notes the rechargeable Activa RC has a battery life of nine to 15 years. In intrathecal drug delivery, its SynchroMed II pump remains the segment leader for chronic, severe spasticity.
Medtronic also tops iData Research’s ranking of the leading global spine companies, underlining its reach across pain and spine care.
Recent development: in April 2024 Medtronic won FDA approval for Inceptiv, its first closed-loop spinal cord stimulator, and at the North American Neuromodulation Society 2025 meeting it reported 12-month data in which half of patients reduced or stopped opioid pain medication.
What makes Abbott a top pain management device company
Abbott is the second-leading pain management device company in the U.S.
It holds significant share in spinal cord stimulation, deep brain stimulation and radiofrequency ablation. Its spinal cord stimulation range includes the recharge-free Proclaim Elite and the Prodigy MRI systems, and its Proclaim generators connect to mobile devices over Bluetooth for software upgrades.
In radiofrequency ablation, Abbott offers classic and SL premium needle lines in curved and straight options, paired with its IonicRF generator, which runs four independently controlled channels for treating several sites at once.
Recent development: Abbott’s Eterna spinal cord stimulation system won a 2025 Edison Award gold in chronic-condition treatment, recognition for a rechargeable implant that needs charging only about five times a year.
Why Boston Scientific ranks among the top pain management companies
Boston Scientific is the third-leading pain management device company in the U.S.
It holds significant share in spinal cord stimulation, deep brain stimulation and radiofrequency ablation. Its Vercise Genus is a fourth-generation deep brain stimulation device, available in rechargeable and non-rechargeable versions, with an eight-contact directional lead that steers current toward the target.
Boston Scientific is active across the entire radiofrequency ablation market. It offers SideKick cannulas along with straight and curved needles, all run by its G4 generator with multi-electrode control.
Recent development: in August 2025 Boston Scientific received FDA 510(k) clearance for its GX1 radiofrequency generator, a 50-watt system for creating radiofrequency lesions to treat pain.
How big is the U.S. pain management device market?
The U.S. pain management device market is worth $6.2 billion in 2025 and is expected to reach $7.8 billion, a compound annual growth rate of 3.4%, according to iData Research.
The report covers 13 device segments, from neurostimulators to infusion pumps and radiofrequency ablation. Growth is led by the shift toward non-opioid pain relief. The opioid crisis has pushed physicians and patients toward implantable devices that deliver electrical therapy instead of drugs.
Rising rates of chronic pain and a move toward minimally invasive, outpatient care add further demand. These drivers favor the companies with the broadest neurostimulation and ablation portfolios, which is why Medtronic, Abbott and Boston Scientific sit at the top.
Pain management device companies: frequently asked questions
Who is the largest pain management device company in 2026?
Medtronic is the largest pain management device company in the U.S. in 2026. iData Research ranks it first overall, with leading share in spinal cord stimulation, deep brain stimulation, intrathecal pumps and radiofrequency ablation.
What are the top three pain management device companies?
The top three pain management device companies are Medtronic, Abbott and Boston Scientific. All three lead across the neurostimulation and radiofrequency ablation segments tracked by iData Research.
How fast is the pain management device market growing?
The U.S. pain management device market is growing at a 3.4% CAGR, rising from $6.2 billion in 2025 toward $7.8 billion, according to iData Research.
What is driving demand for pain management devices?
Demand is driven mainly by the shift toward non-opioid pain relief, rising rates of chronic pain, and the move to minimally invasive, outpatient care.
For the full ranking, market share by segment and detailed forecasts, see the iData Research U.S. Pain Management Device Market report.
Turn market painpoints into opportunities
Explore how procedure trends and competitor positioning create clear openings for industry experts in the market.
